



## Utility patent has been approved in China

**ProstaLund AB has received a positive notification that a utility patent application for a medical kit including a further development of the Schelin Catheter™ has been approved in China.**

A utility patent is a form of simpler patent that can be maintained for 10 years, in this case until the year 2031.

Today, the Schelin Catheter™ is used as a standard for CoreTherm® BPH treatment from ProstaLund. Then local anesthesia with adrenaline is given via the catheter and this contributes to both a substantially painless treatment and a reduced blood flow, which in turn has shortened the treatment to today's about 10-15 minutes. The Schelin Catheter™ looks at first glance like a regular urinary catheter but has an extra channel through which a thermoplastic cannula is inserted. The cannula is connected to a syringe and thus drugs can be injected directly into the prostate.

The Schelin® Catheter is an intraprostatic injection tool and can probably also be successfully used to provide local anesthesia for other prostate treatments and to provide medicines in the treatment of prostate diseases such as benign prostate enlargement (BPE/BPH), prostatitis, and prostate cancer. Last year, ProstaLund also filed patent applications in Europe and the United States regarding various methods of using Schelin Catheter™.

This approval is important in our effort to strengthen intellectual property protection around the Schelin Catheter™ and its future uses ", says CEO Johan Wennerholm in a comment.

**For further information, please contact:**

---

Johan Wennerholm, CEO  
Tel. +46 (0) 730 429997  
Email: [johan.wennerholm@prostalund.com](mailto:johan.wennerholm@prostalund.com)



PRESS RELEASE  
01 February 2022 09:05:00 CET

## About ProstaLund

---

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

### **Certified Adviser:**

Västra Hamnen Corporate Finance AB

Phone: +46 40 200 250

E-mail: ca@vhcorp.se

*This information is information that ProstaLund is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-02-01 09:05 CET.*

## Attachments

---

Utility patent has been approved in China